MPA at high doses in advanced breast cancer: a statistical evaluation.
A computerized, retrospective analysis of clinical and pharmacokinetic data relative to 380 cancer patients under medroxyprogesterone acetate (MPA) therapy has been carried out. A bioavailability:objective- response correlation was found only for mammary cancer patients with visceral metastases and a pain-control effect was observed in advanced cancer patients when MPA plasma levels were higher than 150-200 ng/ml. Discriminant analysis of the known prognostic factors for breast cancer indicates that receptorial status, site of predominant metastases, basal alkaline phosphatase and free interval are good predictors for possible clinical response, while the behavior of prolactin and previous treatments are predictors for non-response. There is no improvement in the efficacy of prediction in combining more than one prognostic factor.
D000284:Administration, Oral; D001682:Biological Availability; D001943:Breast Neoplasms / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D003201:Computers; D005260:Female; D006801:Humans; D007273:Injections, Intramuscular; D007700:Kinetics; D008525:Medroxyprogesterone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000097:blood / Q000627:therapeutic use; D017258:Medroxyprogesterone Acetate; D012189:Retrospective Studies; D013223:Statistics as Topic
D017258:Medroxyprogesterone Acetate; D008525:Medroxyprogesterone